Market Performance - The Medical Health Index (980016) closed at 7021.34 points, down 1.08%, with a trading volume of 33.906 billion yuan and a turnover rate of 1.07% [1] - Among the index constituents, 5 stocks rose while 45 stocks fell, with Yirui Technology leading the gainers at 1.82% and Changchun High-tech leading the decliners at 3.91% [1] Key Constituents - The top ten constituents of the Medical Health Index include: - WuXi AppTec (13.58% weight) at 108.75 yuan, up 1.23% with a market cap of 320.976 billion yuan - Hengrui Medicine (10.87% weight) at 69.65 yuan, down 2.03% with a market cap of 462.281 billion yuan - Mindray Medical (8.17% weight) at 235.00 yuan, down 1.18% with a market cap of 284.924 billion yuan - United Imaging Healthcare (4.14% weight) at 147.90 yuan, down 1.40% with a market cap of 121.893 billion yuan - Other notable constituents include Pianzai Shou, Yier Eye Hospital, Kelun Pharmaceutical, Xinhecheng, Fosun Pharma, and Yixiao Aoshi [1] Capital Flow - The Medical Health Index constituents experienced a net outflow of 2.29 billion yuan from institutional investors, while retail investors saw a net inflow of 2.013 billion yuan [3] - Notable capital flows include: - Mindray Medical with a net inflow of 98.789 million yuan from institutional investors and a net outflow of 10.5 million yuan from speculative funds - Changchun High-tech with a net inflow of 67.986 million yuan from institutional investors and a significant net outflow from speculative funds [3]

| 姓名 | 离任职务 | 离任 | 原定任期 | 离任原 | 是否继续在 上市公司及 | 具体职务 | 是否存在未履行 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 时间 | 到期日 | 因 | 其控股子公 | （如适用） | 完毕的公开承诺 | | | | | | | 司任职 | | | | 黄曲荣 | 非独立董 | 2025 年9月 | 2026 年 5 | 工作调 | 是 | 职工代表 董事、济川 药业集团 | 否 | | | 事 | | 月 7 日 | 整 | | | | | | | 19 日 | | | | 有限公司 | | | | | | | | | 董事 | | （一）提前离任的基本情况 （二）离任对公司的影响 证券代码： 600566 证券简称： 济川药业 公告编号： 2025-083 湖北济川药业股份有限公司 关于非独立董事离任暨选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 湖北济川药业股份有限公 ...

北京植德律师事务所 关于湖北济川药业股份有限公司 关于湖北济川药业股份有限公司 2025 年第一次临时股东大会的 法律意见书 植德京（会）字[2025]0130 号 2025 年第一次临时股东大会的 法律意见书 植德京（会）字[2025]0130号 二〇二五年九月 北京市东城区东直门南大街 1 号来福士中心办公楼 12 层 邮编：100007 12th Floor, Raffles City Beijing Offices Tower, No.1 Dongzhimen South Street,Dongcheng District, Beijing 100007 P.R.C. 电话（Tel）: 010-56500900 传真（Fax）: 010-56500999 www.meritsandtree.com 北京植德律师事务所 致：湖北济川药业股份有限公司（贵公司） 北京植德律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席 并见证贵公司 2025 年第一次临时股东大会（以下简称"本次会议"）。 本所律师参加本次会议进行见证，并根据《中华人民共和国公司法》（以下简称 "《公司法》"）、《中华人民共和国 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 9 月 19 日 证券代码：600566 证券简称：济川药业 公告编号：2025-084 湖北济川药业股份有限公司 2025年第一次临时股东大会决议公告 审议结果：通过 表决情况： (二)股东大会召开的地点：江苏省泰兴市大庆西路宝塔湾济川药业会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 661 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 589,409,721 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 64.1115 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，采取现场投票和网络投票相结合的方式召开， 现场会议由公司董事长曹龙祥先生主持。本次会议的召集、召开及 ...

Core Viewpoint - Jichuan Pharmaceutical's financial performance continues to decline, with significant drops in revenue and net profit in the first half of 2025, raising concerns about the company's future prospects due to challenges from core product sales and ongoing medical procurement policies [1][2][3]. Financial Performance - In the first half of 2025, Jichuan Pharmaceutical reported revenue of 2.75 billion yuan, a year-on-year decrease of 31.9%, and a net profit of 724 million yuan, down 45.9% [2]. - The second quarter of 2025 saw revenue of 1.22 billion yuan, a decline of 25.03% year-on-year and 19.8% quarter-on-quarter, with net profit at 284 million yuan, down 42.39% year-on-year and 35.5% quarter-on-quarter [2]. Core Products and Market Challenges - The sales of Jichuan's key products, Pudilan Anti-inflammatory Oral Liquid and Children's Chiqiao Qingre Granules, have significantly decreased, with their combined sales accounting for only 49.51% of total revenue in the first half of 2025, down from 60.12% in 2024 [2][3]. - The decline in sales is attributed to changes in market demand and the impact of medical procurement policies, which have affected the pricing and availability of these products [2][4]. Historical Context - Jichuan's revenue surged from 7.63 billion yuan in 2021 to 9.655 billion yuan in 2023 due to increased demand for respiratory disease treatments, but has since fallen to a historical low in 2025 [3]. - The company's core product, Pudilan, has been removed from several provincial medical insurance catalogs, leading to decreased patient purchasing willingness [3]. Competitive Landscape - The market for Jichuan's products is becoming increasingly competitive, with numerous alternatives available, including well-known brands that pose a threat to Pudilan's market share [4][7]. - Jichuan's other important product, Rabeprazole Sodium Enteric-Coated Capsules, faces pricing pressures from national procurement policies, which could further impact its market position [4]. Strategic Initiatives and Challenges - Jichuan is attempting to diversify by entering the personal care and innovative drug markets, but results have been limited, with personal care products generating only 89 million yuan in sales in 2023 [5][6]. - The company has initiated collaborations for innovative drug development, but faces stiff competition in these areas, making it difficult to establish a strong market presence [6][7]. Research and Development Focus - Jichuan has historically prioritized marketing over research and development, with R&D expenses constituting only 5.55% of total revenue in 2024, which raises concerns about its ability to innovate effectively [6][8]. - The company has several products in the pipeline, but the competitive nature of the market poses significant challenges to their success [6][7].

（文章来源：证券日报） 证券日报网讯 9月16日晚间，济川药业发布公告称，近日，公司全资子公司陕西东科制药有限责任公司 （简称"陕西东科"）收到利多卡因凝胶贴膏《药品注册证书》。 ...

Core Points - The Medical Health R Index (480016) closed at 8278.77 points, down 0.33%, with a trading volume of 31.765 billion yuan and a turnover rate of 1.08% [1] - Among the index constituents, 18 stocks rose while 31 fell, with Yirui Technology leading the gainers at a 4.4% increase and Zexin Pharmaceutical leading the decliners at a 5.37% decrease [1] Index Constituents Summary - The top ten constituents of the Medical Health R Index include: - WuXi AppTec (sh603259) with a weight of 13.58% and a market cap of 315.96 billion yuan [1] - Hengrui Medicine (sh600276) with a weight of 10.87% and a market cap of 458.96 billion yuan [1] - Mindray Medical (sz300760) with a weight of 8.17% and a market cap of 290.50 billion yuan [1] - United Imaging Healthcare (sh688271) with a weight of 4.14% and a market cap of 126.08 billion yuan [1] - Other notable constituents include Pianzai Shou (sh600436), Yierfu Technology (sz300015), Kelun Pharmaceutical (sz002422), New Hope Liuhe (sz002001), Fosun Pharma (sh600196), and East China Pharmaceutical (sz000963) [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 1.638 billion yuan, while retail investors saw a net inflow of 1.098 billion yuan [1] - Notable capital flows include: - Kailai Ying (002821) with a main fund net inflow of 101 million yuan [2] - Mindray Medical (300760) with a main fund net inflow of approximately 90.77 million yuan [2] - Yuyue Medical (002223) with a main fund net inflow of 24.60 million yuan [2]

证券代码： 600566 证券简称： 济川药业 公告编号： 2025-082 湖北济川药业股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 1 二、药物其他情况 利多卡因是一种酰胺类局部麻醉剂，通过抑制神经冲动发生与传导所需的离 子通道而起到稳定神经细胞膜作用。利多卡因凝胶贴膏最早于 1999 年 3 月在美 国上市，持证商为 Teikoku Pharma USA, Inc，商品名为 Lidoderm ®，上市剂型为 贴膏剂，适应症为用于缓解带状疱疹后遗神经痛。 陕西东科的利多卡因凝胶贴膏注册分类为化学药品 3 类，按照与参比制剂质 量和疗效一致的技术要求审评并获批，批准后视同通过仿制药质量和疗效一致性 评价，用于缓解带状疱疹后神经痛，用于无破损皮肤。 截至目前，除原研进口外，国内已有 4 家企业（含陕西东科）获批利多卡因 凝胶贴膏。据米内网数据显示，2024 年中国城市公立医院利多卡因凝胶贴膏的 销售额为 6,475 万元。 截至本公告披露日，该药品累计研发支出约 1,749.2 ...

每经AI快讯，济川药业（SH 600566，收盘价：25.54元）9月16日晚间发布公告称，近日，湖北济川药 业股份有限公司全资子公司陕西东科制药有限责任公司收到国家药品监督管理局核准签发的利多卡因凝 胶贴膏《药品注册证书》。 2024年1至12月份，济川药业的营业收入构成为：清热解毒类占比33.53%，儿科类占比28.11%，消化类 占比14.41%，其他行业占比9.94%，呼吸类占比8.13%。 截至发稿，济川药业市值为235亿元。 每经头条（nbdtoutiao）——海拔4306米现"秦始皇密令"，获官方"身份认定"！古文字学家刘钊：秦人 寻仙采药足迹确至青藏高原 （记者 王晓波） ...

济川药业（600566）(600566.SH)公告，公司全资子公司陕西东科制药有限责任公司(简称"陕西东科")收 到国家药品监督管理局核准签发的利多卡因凝胶贴膏《药品注册证书》。利多卡因是一种酰胺类局部麻 醉剂，通过抑制神经冲动发生与传导所需的离子通道而起到稳定神经细胞膜作用。 ...